U.S. License Holder:
Eisai Inc.
Date of License:
January-06-2023
Last Update:
Oct-23-2024
FDA-Approved Indications
LEQEMBI (lecanemab-irmb) is indicated for the treatment of Alzheimer's disease. Treatment with Leqembi should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.